Comparative effects of chlorpyrifos in wild type and cannabinoid Cb1 receptor knockout mice

Toxicology and Applied Pharmacology

Volumn 256, Issue 3, 2011, Pages 324-329

  Baireddy, Praveena ^a   Liu, Jing ^a   Hinsdale, Myron ^a   Pope, Carey ^a  

^a OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

Acetylcholinesterase; Acute toxicity; Endocannabinoids; Insecticide; Organophosphorus

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ACETYLCHOLINE; CANNABINOID 1 RECEPTOR; CHLORPYRIFOS; CHOLINESTERASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CEREBELLUM; CHOLINERGIC SYSTEM; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENOTYPE; HEART; HIPPOCAMPUS; MALE; MOUSE; NEUROCHEMISTRY; NONHUMAN; TOXICITY TESTING;

ACETYLCHOLINE; ANIMALS; CEREBELLUM; CEREBRAL CORTEX; CHLORPYRIFOS; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HEART; HIPPOCAMPUS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROTOXICITY SYNDROMES; RECEPTOR, CANNABINOID, CB1;

ARACHIS HYPOGAEA; MUS; RATTUS;

EID: 80855148211     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.05.018     Document Type: Article

References (53)

1. Atwood B.K., Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br. J. Pharmacol. 2010, 160:467-479.
2. Begg M., Pacher P., Bátkai S., Osei-Hyiaman D., Offertáler L., Mo F.M., Liu J., Kunos G. Evidence for novel cannabinoid receptors. Pharmacol. Ther. 2005, 106:133-145.
3. Casida J.E., Quistad G.B. Serine hydrolase targets of organophosphorus toxicants. Chem. Biol. Interact. 2005, 157-158:277-283.
4. Coutts A.A., Anavi-Goffer S., Ross R.A., MacEwan D.J., Mackie K., Pertwee R.G., Irving A.J. Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons. J. Neurosci. 2001, 21:2425-2433.
5. Chanda P.K., Gao Y., Mark L., Btesh J., Strassle B.W., Lu P., Piesla M.J., Zhang M.Y., Bingham B., Uveges A., Kowal D., Garbe D., Kouranova E.V., Ring R.H., Bates B., Pangalos M.N., Kennedy J.D., Whiteside G.T., Samad T.A. Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system. Mol. Pharmacol. 2010, 78:996-1003.
6. De Filippis D., Steardo A., D'Amico A., Scuderi C., Cipriano M., Esposito G., Iuvone T. Differential cannabinoid receptor expression during reactive gliosis: a possible implication for a nonpsychotropic neuroprotection. ScientificWorldJournal 2009, 9:229-235.
7. Degroot A., Köfalvi A., Wade M.R., Davis R.J., Rodrigues R.J., Rebola N., Cunha R.A., Nomikos G.G. CB1 receptor antagonism increases hippocampal acetylcholine release: site and mechanism of action. Mol. Pharmacol. 2006, 70:1236-1245.
8. Di Marzo V., Bifulco M., De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discov. 2004, 3:771-784.
9. Dinh T.P., Freund T.F., Piomelli D. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem. Phys. Lipids 2002, 121:149-158.
10. Dolezal V., Tucek S. The effects of 4-aminopyridine and tetrodotoxin on the release of acetylcholine from rat striatal slices. Naunyn Schmiedebergs Arch. Pharmacol. 1983, 323:90-95.
11. Eto M. Organophosphorus Pesticides: Organic and Biological Chemistry 1974, CRC Press, Cleveland, Ohio, 387 pp.
12. Freund T.F., Katona I., Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 2003, 83:1017-1066.
13. Gessa G.L., Casu M.A., Carta G., Mascia M.S. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A. Eur. J. Pharmacol. 1998, 355:119-124.
14. Gifford A.N., Ashby C.R. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. J. Pharmacol. Exp. Ther. 1996, 277:1431-1436.
15. Gifford A.N., Tang Y., Gatley S.J., Volkow N.D., Lan R., Makriyannis A. Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices. Neurosci. Lett. 1997, 238:84-86.
16. Gifford A.N., Bruneus M., Gatley S.J., Volkow N.D. Cannabinoid receptor-mediated inhibition of acetylcholine release from hippocampal and cortical synaptosomes. Br. J. Pharmacol. 2000, 131:645-650.
17. Glowinski J., Iversen L.L. Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. J. Neurochem. 1966, 13:655-669.
18. Grube A., Donaldson D., Kiely T., Wu L. Pesticides industry sales and usage: 2006 and 2007 market estimates. Office of Pesticide Programs, Office of Chemical Safety and Pollution Prevention 2011, U.S. Environmental Protection Agency, Washington, DC.
19. Hashimotodani Y., Ohno-Shosaku T., Kano M. Endocannabinoids and synaptic function in the CNS. Neuroscientist 2007, 13:127-137.
20. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:1932-1936.
21. Johnson C.D., Russell R.L. Radiometric method of acetylcholinesterase measurement. Anal. Biochem. 1975, 64:229-238.
22. Karanth S., Pope C. Carboxylesterase and A-esterase activities during maturation and aging: relationship to the toxicity of chlorpyrifos and parathion in rats. Toxicol. Sci. 2000, 58:282-289.
23. Karanth S., Liu J., Mirajkar N., Pope C. Effects of acute chlorpyrifos exposure on in vivo acetylcholine accumulation in rat striatum. Toxicol. Appl. Pharmacol. 2006, 216:150-156.
24. Kathmann M., Weber B., Zimmer A., Schlicker E. Enhanced acetylcholine release in the hippocampus of cannabinoid CB(1) receptor-deficient mice. Br. J. Pharmacol. 2001, 132:1169-1173.
25. Kiely T., Donaldson D., Grube A. Pesticides industry sales and usage, 2000 and 2001 market estimates. Office of Prevention, Pesticides, and Toxic Substances 2004, U.S. Environmental Protection Agency, Washington, DC.
26. Kim J., Isokawa M., Ledent C., Alger B.E. Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus. J. Neurosci. 2002, 22:10182-10191.
27. 2+ levels and transmitter release in the hippocampus. Br. J. Pharmacol. 2007, 151:551-563.
28. Kreitzer F.R., Stella N. The therapeutic potential of novel cannabinoid receptors. Pharmacol. Ther. 2009, 122:83-96.
29. Liu J., Pope C.N. Effects of chlorpyrifos on high-affinity choline uptake and [3H]hemicholinium-3 binding in rat brain. Fundam. Appl. Toxicol. 1996, 34:84-90.
30. Liu J., Pope C.N. Comparative presynaptic neurochemical changes in rat striatum following exposure to chlorpyrifos or parathion. J. Toxicol. Environ. Health A 1998, 53:531-544.
31. Liu J., Chakraborti T., Pope C. In vitro effects of organophosphorus anticholinesterases on muscarinic receptor-mediated inhibition of acetylcholine release in rat striatum. Toxicol. Appl. Pharmacol. 2002, 178:102-108.
32. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
33. Matsuda L.A., Bonner T.I., Lolait S.J. Localization of cannabinoid receptor mRNA in rat brain. J. Comp. Neurol. 1993, 327:535-550.
34. Mileson B.E., Chambers J.E., Chen W.L., Dettbarn W., Ehrich M., Eldefrawi A.T., Gaylor D.W., Hamernik K., Hodgson E., Karczmar A.G., Padilla S., Pope C.N., Richardson R.J., Saunders D.R., Sheets L.P., Sultatos L.G., Wallace K.B. Common mechanism of toxicity: a case study of organophosphorus pesticides. Toxicol. Sci. 1998, 41:8-20.
35. Mortensen S.R., Brimijoin S., Hooper M.J., Padilla S. Comparison of the in vitro sensitivity of rat acetylcholinesterase to chlorpyrifos-oxon: what do tissue IC50 values represent?. Toxicol. Appl. Pharmacol. 1998, 148:46-49.
36. Nallapaneni A., Liu J., Karanth S., Pope C. Modulation of paraoxon toxicity by the cannabinoid receptor agonist WIN 55,212-2. Toxicology 2006, 227:173-183.
37. Nallapaneni A., Liu J., Karanth S., Pope C. Pharmacological enhancement of endocannabinoid signaling reduces the cholinergic toxicity of diisopropylfluorophosphate. Neurotoxicology 2008, 29:1037-1043.
38. Németh B., Ledent C., Freund T.F., Hájos N. CB1 receptor-dependent and -independent inhibition of excitatory postsynaptic currents in the hippocampus by WIN 55,212-2. Neuropharmacology 2008, 54:51-57.
39. Ohno-Shosaku T., Matsui M., Fukudome Y., Shosaku J., Tsubokawa H., Taketo M.M., Manabe T., Kano M. Postsynaptic M1 and M3 receptors are responsible for the muscarinic enhancement of retrograde endocannabinoid signalling in the hippocampus. Eur. J. Neurosci. 2003, 18:109-116.
40. Pertwee R.G. Pharmacological actions of cannabinoids. Handb. Exp. Pharmacol. 2005, 168:1-51.
41. Pope C.N., Chakraborti T.K., Chapman M.L., Farrar J.D. Long-term neurochemical and behavioral effects induced by acute chlorpyrifos treatment. Pharmacol. Biochem. Behav. 1992, 42:251-256.
42. Pope C.N., Chaudhuri J., Chakraborti T.K. Organophosphate-sensitive cholinergic receptors: possible role in modulation of anticholinesterase-induced toxicity. Pages 305-312 in Enzymes of the Cholinesterase Family 1995, Plenum, New York. A.S. Balasubramanian, B.P. Doctor, P. Taylor, D.M. Quinn (Eds.).
43. Pope C.N., Liu J., Nallapaneni A., Wright L.K.M., Baireddy P., Parsons L. The modulation of neurotoxicity by endocannabinoids. Abstracts, 25th International Neurotoxicology Conference, Rochester, NY 2008, October 12-16, 2008.
44. Pope C., Mechoulam R., Parsons L. Endocannabinoid signaling in neurotoxicity and neuroprotection. Neurotoxicology 2010, 31:562-571.
45. Quistad G.B., Sparks S.E., Segall Y., Nomura D.K., Casida J.E. Selective inhibitors of fatty acid amide hydrolase relative to neuropathy target esterase and acetylcholinesterase: toxicological implications. Toxicol. Appl. Pharmacol. 2002, 179:57-63.
46. Quistad G.B., Klintenberg R., Caboni P., Liang S.N., Casida J.E. Monoacylglycerol lipase inhibition by organophosphorus compounds leads to elevation of brain 2-arachidonoylglycerol and the associated hypomotility in mice. Toxicol. Appl. Pharmacol. 2006, 211:78-83.
47. Steffens M., Szabo B., Klar M., Rominger A., Zentner J., Feuerstein T.J. Modulation of electrically evoked acetylcholine release through cannabinoid CB1 receptors: evidence for an endocannabinoid tone in the human neocortex. Neuroscience 2003, 120:455-465.
48. Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 2010, 58:1017-1030.
49. Tsou K., Brown S., Sañudo-Peña M.C., Mackie K., Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998, 83:393-411.
50. Tzavara E.T., Wade M., Nomikos G.G. Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action. J. Neurosci. 2003, 23:9374-9384.
51. Wright L.K., Liu J., Nallapaneni A., Pope C.N. Behavioral sequelae following acute diisopropylfluorophosphate intoxication in rats: comparative effects of atropine and cannabinomimetics. Neurotoxicol. Teratol. 2010, 32:329-335.
52. Zhang H., Liu J., Pope C.N. Age-related effects of chlorpyrifos on muscarinic receptor-mediated signaling in rat cortex. Arch. Toxicol. 2002, 75:676-684.
53. Zimmer A., Zimmer A.M., Hohmann A.G., Herkenham M., Bonner T.I. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:5780-5785.